LLY

1,036.74

+2.99%↑

JNJ

229.66

-0.1%↓

ABBV

214.11

+0.75%↑

UNH

384.59

-0.16%↓

AZN

188.63

+0.6%↑

LLY

1,036.74

+2.99%↑

JNJ

229.66

-0.1%↓

ABBV

214.11

+0.75%↑

UNH

384.59

-0.16%↓

AZN

188.63

+0.6%↑

LLY

1,036.74

+2.99%↑

JNJ

229.66

-0.1%↓

ABBV

214.11

+0.75%↑

UNH

384.59

-0.16%↓

AZN

188.63

+0.6%↑

LLY

1,036.74

+2.99%↑

JNJ

229.66

-0.1%↓

ABBV

214.11

+0.75%↑

UNH

384.59

-0.16%↓

AZN

188.63

+0.6%↑

LLY

1,036.74

+2.99%↑

JNJ

229.66

-0.1%↓

ABBV

214.11

+0.75%↑

UNH

384.59

-0.16%↓

AZN

188.63

+0.6%↑

Search

Moleculin Biotech Inc

Open

2.37 3.04

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

2.27

Max

2.38

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+793.62% upside

Moleculin Biotech Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

20. Mai 2026, 23:31 UTC

Heiße Aktien

Stocks to Watch: Intuit, Applied Digital, Osisko, Banzai

20. Mai 2026, 22:52 UTC

Wichtige Markttreiber

Osisko Shares Fall on Planned Convertible Notes Offering

20. Mai 2026, 23:47 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

20. Mai 2026, 23:47 UTC

Market Talk

Nikkei May Rise on Continued AI Enthusiasm -- Market Talk

20. Mai 2026, 23:44 UTC

Ergebnisse

Musk Is In Total Control of SpaceX. The IPO Filing Has Finally Come. -- Barrons.com

20. Mai 2026, 23:35 UTC

Market Talk

Gold Edges Lower Amid Slightly Higher U.S. Treasury Yields -- Market Talk

20. Mai 2026, 23:30 UTC

Market Talk

Goodman Well-Placed for Earnings Guidance Upgrade -- Market Talk

20. Mai 2026, 23:17 UTC

Market Talk

Global Equities Roundup: Market Talk

20. Mai 2026, 23:17 UTC

Market Talk

Ryman Healthcare Bull Focusing on Three Areas in FY26 Result -- Market Talk

20. Mai 2026, 23:15 UTC

Market Talk

Mainfreight's FY26 Profit Fall May Mask Improving Performance -- Market Talk

20. Mai 2026, 23:14 UTC

Ergebnisse

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 4th Update

20. Mai 2026, 23:02 UTC

Market Talk

KMD Brands Faces Two Testing Hurdles -- Market Talk

20. Mai 2026, 22:57 UTC

Market Talk

Infratil's Other Assets Deserve Attention, Too -- Market Talk

20. Mai 2026, 22:57 UTC

Market Talk

Global Energy Roundup: Market Talk

20. Mai 2026, 22:57 UTC

Market Talk

Global Equities Roundup: Market Talk

20. Mai 2026, 22:51 UTC

Market Talk

Australia Shares Set to Rise, Continue Whipsaw Week -- Market Talk

20. Mai 2026, 22:51 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

20. Mai 2026, 22:27 UTC

Market Talk

SpaceX Says It Has Largest Addressable Market in 'Human History' -- Market Talk

20. Mai 2026, 22:14 UTC

Market Talk

Moody's Downgrades Mexico's Sovereign Rating -- Market Talk

20. Mai 2026, 22:10 UTC

Ergebnisse

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 3rd Update

20. Mai 2026, 22:00 UTC

Ergebnisse

Intuit Stock Falls on Earnings -- and the Company Plans to Cut 17% of Its Workforce -- Barrons.com

20. Mai 2026, 21:38 UTC

Ergebnisse
Akquisitionen, Fusionen, Übernahmen

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 2nd Update

20. Mai 2026, 21:27 UTC

Ergebnisse

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- Update

20. Mai 2026, 21:20 UTC

Ergebnisse

Nvidia CFO: Edge Computing Demand Fell Modestly Due to Higher Memory Prices

20. Mai 2026, 21:19 UTC

Ergebnisse

Nvidia Still Uncertain Whether Shipping to China Will Be Allowed, CFO Says

20. Mai 2026, 21:18 UTC

Ergebnisse

Nvidia on Track to Start Production Shipments of Vera Rubin in Second Half of This Year, CFO Says

20. Mai 2026, 21:17 UTC

Ergebnisse

Nvidia Projects $20B in CPU Revenue This Year, CFO Says

20. Mai 2026, 21:17 UTC

Ergebnisse

Nvidia CFO: Every Major Hyperscaler Engaged in Deploying Vera CPU

20. Mai 2026, 21:17 UTC

Ergebnisse

Nvidia's Vera CPU Opens New $200B Market, CFO Says

20. Mai 2026, 21:16 UTC

Ergebnisse

SpaceX IPO Filing Finally Comes. Mars, Musk, and More Big Things to Watch. -- Barrons.com

Peer-Vergleich

Kursveränderung

Moleculin Biotech Inc Prognose

Kursziel

By TipRanks

793.62% Vorteil

12-Monats-Prognose

Durchschnitt 21 USD  793.62%

Hoch 31 USD

Tief 10 USD

Basierend auf 3 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Moleculin Biotech Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

3 ratings

3

Buy

0

Halten

0

Sell

Finanzen

$

help-icon Live chat